WALKER WAYNE REMELL 4/A

What Happened
Wayne Remell, a director of PharmaCyte Biotech, was listed on an amended Form 4 for an "other acquisition or disposition" (derivative) dated 2026-03-31 that shows 0 shares acquired and no price or value. The filing footnote clarifies the reported grant was made in error and has been cancelled—no securities were issued and no consideration exchanged. This is neither a purchase nor a sale by the insider.

Key Details

• Filing type: Amended Form 4 (filed 2026-07-17) for period ending 2026-03-31.
• Reported transaction date: 2026-03-31; transaction coded as "J" (other acquisition/disposition related to derivatives).
• Shares recorded in the transaction: 0; Price: N/A; Total value: N/A.
• Footnote: F1 — "The reported grant was made in error and has been cancelled."
• Shares owned after transaction: not changed by this filing (no securities issued).
• No evidence of a trade plan or tax withholding; this appears to be an administrative correction rather than trading activity.

Context
This amended filing corrects an erroneous award report and does not indicate insider buying or selling interest. Retail investors should treat it as an administrative update and watch for future filings if Remell engages in actual purchases or dispositions.